Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
4.55
Nov 16 • 3:44 PM ET Dollar change-0.30 Percentage change(-6.19%)
Aftermarket Close
4.55
Aftermarket • 4:15 PM ET Dollar change0.00 Percentage change(0.00%)
Index
-
Market Cap
36.68M
Enterprise Value
41.27M
Income
-1.95M
Sales
31.13M
Book/sh
-2.03
Cash/sh
0.52
Employees
76
IPO
Apr 04, 1994
P/E
-
Forward P/E
-
PEG
-
P/S
1.18
P/B
-
P/C
8.67
P/FCF
7.89
EV/EBITDA
26.80
EV/Sales
1.33
Quick Ratio
0.82
Current Ratio
0.86
Debt/Eq
-
LT Debt/Eq
-
Option/Short
No / Yes
EPS (ttm)
-0.24
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS past 3/5Y
- -
Sales past 3/5Y
1.33% 0.27%
EPS Y/Y TTM
-314.41%
Sales Y/Y TTM
-1.96%
EPS Q/Q
69.72%
Sales Q/Q
-0.02%
Insider Own
47.86%
Insider Trans
0.00%
Inst Own
13.14%
Inst Trans
-1.32%
ROA
-3.10%
ROE
-
ROIC
-
Gross Margin
76.17%
Oper. Margin
0.61%
Profit Margin
-6.25%
SMA20
-7.99%
SMA50
1.69%
SMA200
20.82%
Trades
Shs Outstand
8.06M
Shs Float
4.20M
52W High
5.45 -16.44%
52W Low
2.72 67.28%
Volatility
10.61% 8.45%
ATR (14)
0.43
RSI (14)
45.60
Beta
0.45
Rel Volume
1.63
Avg Volume
13.53K
Volume
22,066
Perf Week
-7.43%
Perf Month
2.94%
Perf Quarter
15.78%
Perf Half Y
28.17%
Perf YTD
32.27%
Perf Year
10.71%
Perf 3Y
7.95%
Perf 5Y
-58.00%
Perf 10Y
33.43%
Prev Close
4.85
Price
4.55
Change %
-6.19%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
TAYMANS JILL MVP Finance, CFOMay 28 '26Option Exercise3.107,50023,25052,896May 29 04:30 PM
Cryo-Cell International, Inc. is a cord blood bank, which engages in providing stem cell cryopreservation services and advancing regenerative medicine. It operates through the following segments: Umbilical Cord Blood and Cord Tissue Stem Cell Service, PrepaCyte CB, and Public Cord Blood Banking. The Umbilical Cord Blood and Cord Tissue Stem Cell Service segment refers to cellular processing and cryogenic storage of umbilical cord blood and cord tissue stem cells for family use. The PrepaCyte CB segment focuses on the manufacture of PrepaCyte CB units, the processing technology used to process umbilical cord blood stem cells. The Public Cord Blood Banking segment relates to the cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company was founded in 1989 and is headquartered in Oldsmar, FL.
Chairman & Co-CEOMr. David I. Portnoy
Co-CEO & DirectorMr. Mark L. Portnoy
CFO & VP of FinanceMs. Jill M. Taymans
Chief Information OfficerMr. Oleg Mikulinsky
Medical Director and Member of Medical & Scientific Advisory BoardDr. Joanne Kurtzberg M.D.